Past events & courses

The WHO Laboratory Biosafety Manual (LBM) serves as a de facto global standard that presents best practices and sets trends in biosafety. The recent publication of the fourth edition expands the thorough, evidence-based and transparent assessment of the risks, allowing safety measures to be balanced with the actual risk of working with biological agents on a case-by-case basis.  A challenging shift from routines based on levels? An opportunity to allow optimizing risk management, in particular in less resourced envrionments? Join us and discuss with two of the LBM4 contributors, active EBSA members, providing their insights on the (r)evolution this version marks and how biosafety professionals can use it in their daily practice.

February 18, 2021 12:00 - 1:30 pm (CST) Biosafety and the COVID-19 Vaccines is intended to provide an overview of the clinical trial development and biosafety considerations of the currently approved COVID-19 vaccines. 

The ISO 35001 standard on “Biorisk management for laboratories and other related organisations - is the first internationally recognized management standard to specifically address hazards associated with laboratories where biological materials are handled at all containment levels.  The course in French is supported by the German Biosecurity Program (sold out)

ONLINE CONFERENCE With the current situation in mind, we provide the possibility to participate online. For further information, please see the attached flyer.

Online event

online webinar by RIVM, The Netherlands

La gestion des risques biologiques dans divers environnements dans lesquels des matières biologiques dangereuses sont utilisées, que ce soit dans la recherche, le diagnostic, les installations de production ou les unités animales, est de la plus haute importance. Les professionnels de la biosécurité jouent très souvent l'interface entre différents acteurs tels que les scientifiques, l'ingénierie, le personnel d'entretien ou de nettoyage. The course in French is supported by the German Biosecurity Program (sold out)

Though the idea for gene therapy was put forward in 1972, it was not until 2003 in China and 10 years later in US, that DNA drug actually appeared on the market. Since then, at least nine gene therapies have been approved for a few cancer types, genetic disorders and viral infections and a great number of research projects and clinical trials are underway in many countries.

The ISO 35001 standard on “Biorisk management for laboratories and other related organisations - is the first internationally recognized management standard to specifically address hazards associated with laboratories where biological materials are handled at all containment levels.  The course with simultaneous translation into Ukrainian language is supported by the German Biosecurity Program (sold out)